Načítá se...
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/ https://ncbi.nlm.nih.gov/pubmed/11129681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|